AbbVie's subcutaneous Skyrizi hit higher endoscopic remission and ulcer-free endoscopy rates vs placebo at week 24 in a phase 3 Crohn's trial. An injectable formulation opens a new delivery channel fo

AbbVie phase 3 injectable Skyrizi Crohn's data release is a biotech catalyst.